Polycystic ovarian disease: clinical considerations.
Although the pathogenesis of the PCO syndrome remains obscure, several endocrine aberrations are clinically measurable in this syndrome. It has been shown that this syndrome is associated with inappropriate gonadotropin secretion and elevated serum LH, A and T levels. Various levels of E2 and E1 have been noted. The evaluation of these individuals should include studies to determine the state of androgen production in them. Treatment should be based upon an understanding of the pathophysiology, a thorough evaluation of androgen production and the patient's expectations based upon age, marital status and desire for pregnancy. The physician's expectations should be related to prevention of endometrial hyperplasia, the restoring of ovulation and amelioration of many of the androgenic side effects seen.
D000735:Androstenedione / Q000378:metabolism*; D003276:Contraceptives, Oral / Q000627:therapeutic use; D004958:Estradiol / Q000378:metabolism; D004970:Estrone / Q000378:metabolism; D005260:Female; D006062:Gonadotropins / Q000378:metabolism*; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000378:metabolism; D010060:Ovulation / Q000187:drug effects; D011085:Polycystic Ovary Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D013739:Testosterone / Q000378:metabolism*; D014626:Vaginal Smears
D003276:Contraceptives, Oral; D006062:Gonadotropins; D004970:Estrone; D013739:Testosterone; D000735:Androstenedione; D007980:Levodopa; D004958:Estradiol; D007986:Luteinizing Hormone